Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821598 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| Hydrochloric Acid SCHEMBL17763476 | 0.99 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| Hydrochloric Acid SCHEMBL17763475 | 0.99 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL13490134 | 0.88 | HTR2C (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL2787453 | 0.88 | HTR2C (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL2579734 | 0.88 | HTR2C (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| Hydrochloric Acid SCHEMBL31066472 | 0.87 | HTR2C (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL17124890 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL4760522 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL8039932 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577205-A2 | SUBSTITUTED PYRAZOLES AND IMIDAZOLES AS OREXIN RECEPTOR ANTAGONISTS COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | Hager Biosciences, LLC (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044351-A2 | SUBSTITUTED PYRAZOLES AND IMIDAZOLES AS OREXIN RECEPTOR ANTAGONISTS COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | HAGER BIOSCIENCES, LLC (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20190276414-A1 | CHIRAL RESOLUTION OF AN INTERMEDIATE OF SUVOREXANT AND COCRYSTALS THEREOF | ENANTIA, S.L. (ES) | 2019-09-12 | — | — | US | disclosed |
| EP-3464250-A1 | CHIRAL RESOLUTION OF AN INTERMEDIATE OF SUVOREXANT AND COCRYSTALS THEREOF | Enantia, S.L. (ES) | 2019-04-10 | — | — | EP | disclosed |
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | SANDOZ AG (CH) | 2018-07-24 | — | — | US | disclosed |
| WO-2017211733-A1 | CHIRAL RESOLUTION OF AN INTERMEDIATE OF SUVOREXANT AND COCRYSTALS THEREOF | ENANTIA, S.L. (ES) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017211733-A1 | CHIRAL RESOLUTION OF AN INTERMEDIATE OF SUVOREXANT AND COCRYSTALS THEREOF | ENANTIA, S.L. (ES) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017133620-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | 浙江华海药业股份有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | SANDOZ AG (CH) | 2017-08-03 | — | — | US | disclosed |
| EP-2392572-A1 | Substituted diazepan compounds as orexin receptor antagonists | Merck Sharp & Dohme Corp. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110195957-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110195957-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110195957-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-08-11 | — | — | US | disclosed |
| US-7951797-B2 | 1-heteroaryl-4-benzoyl-5-(alkyl or cycloalkyl)-1,4-diazepanes; sleep disorders, analgesics, obesity, Parkinson's disease, psychosis and schizophrenia; 6-fluoro-2-{(5R)-5-methyl-4-[2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl}quinazoline for example | MERCK SHARP & DOHME CORP. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951797-B2 | 1-heteroaryl-4-benzoyl-5-(alkyl or cycloalkyl)-1,4-diazepanes; sleep disorders, analgesics, obesity, Parkinson's disease, psychosis and schizophrenia; 6-fluoro-2-{(5R)-5-methyl-4-[2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl}quinazoline for example | MERCK SHARP & DOHME CORP. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951797-B2 | 1-heteroaryl-4-benzoyl-5-(alkyl or cycloalkyl)-1,4-diazepanes; sleep disorders, analgesics, obesity, Parkinson's disease, psychosis and schizophrenia; 6-fluoro-2-{(5R)-5-methyl-4-[2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl}quinazoline for example | MERCK SHARP & DOHME CORP. (US) | 2011-05-31 | — | — | US | disclosed |
| WO-2008069997-A1 | SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080132490-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2008-06-05 | — | — | US | disclosed |
| US-20080132490-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | CYP51A1, CYP3A5, HCRTR2 | SMN1; SMN2 2834/4885NPC1 197/4885RAB9A 772/4885 |
| US-20080132490-A1 | Substituted diazepan orexin receptor antagonists | HCRTR2, HCRTR1, CRHR1 | SMN1; SMN2 2179/4885NPC1 907/4885RAB9A 2537/4885 |
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | CYP51A1, CYP3A5, HCRTR2 | SMN1; SMN2 2983/4885NPC1 162/4885RAB9A 890/4885 |
| US-20110195957-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | SMN1; SMN2 2179/4885NPC1 907/4885RAB9A 2537/4885 |
| US-20190276414-A1 | CHIRAL RESOLUTION OF AN INTERMEDIATE OF SUVOREXANT AND COCRYSTALS THEREOF | HCRTR1, HCRTR2, GLP1R | SMN1; SMN2 2947/4885NPC1 1134/4885RAB9A 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.